FDA Approves ‘Biosimilar’ Drug Ogivri for Breast, Stomach Cancers
FRIDAY, Dec. 1, 2017 (HealthDay News) — Ogivri (trastuzumab-dkst) has been approved by the U.S. Food and Drug Administration as the nation’s first biosimilar drug to treat certain breast and stomach cancers, the agency said Friday in a news release. The maker of a biosimilar, derived from a living organism,Continue Reading